Anavex Life Sciences Corp (AVXL)

[drv17]

"We think differently and we have no fear" Dr. Missling's words spoken in Washington D.C when asked why can Anavex succeed where so many failed.

Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.
NEW YORK, NY – December 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, has been invited to speak at the third annual roundtable on the implementation of the Mental Health Parity Addiction and Equity Act (MHPAEA) of 2008. The event will take place on Tuesday, December 8, 2015 at the U.S. Capitol Visitor Center in Washington, D.C.